179 related articles for article (PubMed ID: 19162218)
1. Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
van Eden W; Lisse J; Prakken B; Albani S
Drug Discov Today; 2010 Jan; 15(1-2):71-7. PubMed ID: 19162218
[TBL] [Abstract][Full Text] [Related]
2. Biologic response modifiers: Indications, implications, and insights.
Davis BP; Ballas ZK
J Allergy Clin Immunol; 2017 May; 139(5):1445-1456. PubMed ID: 28263774
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
Skundric DS
Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
[No Abstract] [Full Text] [Related]
5. Limited efficacy of targeted treatments in Sjögren's syndrome: why?
Tzioufas AG; Goules AV
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):27-28. PubMed ID: 29998826
[No Abstract] [Full Text] [Related]
6. Natural product derived immune-regulatory agents.
Talmadge JE
Int Immunopharmacol; 2016 Aug; 37():5-15. PubMed ID: 26968760
[TBL] [Abstract][Full Text] [Related]
7. Challenges and approaches for the development of safer immunomodulatory biologics.
Sathish JG; Sethu S; Bielsky MC; de Haan L; French NS; Govindappa K; Green J; Griffiths CE; Holgate S; Jones D; Kimber I; Moggs J; Naisbitt DJ; Pirmohamed M; Reichmann G; Sims J; Subramanyam M; Todd MD; Van Der Laan JW; Weaver RJ; Park BK
Nat Rev Drug Discov; 2013 Apr; 12(4):306-24. PubMed ID: 23535934
[TBL] [Abstract][Full Text] [Related]
8. What place for the new biologics in the treatment of necrotising vasculitides.
Jayne D
Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S1-5. PubMed ID: 16859587
[No Abstract] [Full Text] [Related]
9. The development and assessment of biological treatments for children.
Smith EM; Foster HE; Beresford MW
Br J Clin Pharmacol; 2015 Mar; 79(3):379-94. PubMed ID: 24750505
[TBL] [Abstract][Full Text] [Related]
10. Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome.
Dudics S; Langan D; Meka RR; Venkatesha SH; Berman BM; Che CT; Moudgil KD
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149545
[TBL] [Abstract][Full Text] [Related]
11. Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery.
't Hart BA; Laman JD; Kap YS
Clin Pharmacol Ther; 2018 Feb; 103(2):262-270. PubMed ID: 28748631
[TBL] [Abstract][Full Text] [Related]
12. Biologics in Inflammatory Immune-mediated Systemic Diseases.
Moroncini G; Calogera G; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):1008-1016. PubMed ID: 29278213
[TBL] [Abstract][Full Text] [Related]
13. Biologics for the treatment of autoimmune renal diseases.
Holdsworth SR; Gan PY; Kitching AR
Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
[TBL] [Abstract][Full Text] [Related]
14. Biologics in autoimmune diseases.
Shi G; Liu Y
Curr Pharm Biotechnol; 2014; 15(6):509. PubMed ID: 25213358
[No Abstract] [Full Text] [Related]
15. Update on the use of biologics in vasculitides.
Vishwanath S; Relan M; Shen L; Ambrus JL
Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365
[TBL] [Abstract][Full Text] [Related]
16. The use of biologics in the treatment of autoimmune liver disease.
Chang C; Tanaka A; Bowlus C; Gershwin ME
Expert Opin Investig Drugs; 2020 Apr; 29(4):385-398. PubMed ID: 32102572
[No Abstract] [Full Text] [Related]
17. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
Brito-Zerón P; Bosch X; Pérez-de-Lis M; Pérez-Álvarez R; Fraile G; Gheitasi H; Retamozo S; Bové A; Monclús E; Escoda O; Moreno A; López-Guillermo A; Khamashta MA; Ramos-Casals M;
Semin Arthritis Rheum; 2016 Feb; 45(4):391-9. PubMed ID: 26277577
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
[TBL] [Abstract][Full Text] [Related]
19. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
20. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
